Phase 2 RCT | High-dose VE303 reduces recurrent Clostridioides difficile infection rates
17 Apr, 2023 | 13:12h | UTCVE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract